     |
   |
|
|
Selecta's targeted Synthetic Vaccine Particle (tSVP™) product platform enables, for the first time, the highly-precise and modular development of therapeutic and prophylactic vaccines with optimal efficacy, duration of coverage and safety, to greatly improve the lives of patients.
Selecta’s tSVP platform creates fully-integrated synthetic nanoparticle vaccines engineered to mimic the properties of natural pathogens to elicit a maximal immune response. The tSVP vaccines are rationally designed to optimize the presentation of antigens to the nexus of the immune system and ensure a focused and undistracted response. Selecta’s tSVP platform accomplishes this by delivering antigens and adjuvants, within the same biodegradable nanoparticle, directly to antigen-presenting cells. This approach maximizes the immune response while minimizing undesirable off-target effects.
Selecta’s unique tSVP platform includes a self-assembling nanoparticle platform that is synthetic, modular, and engineered for highly-effective targeting to immune cells. The tSVP vaccines incorporate only the essential elements required for a specific, robust immune response, based on precise engineering that is only possible with Selecta’s proprietary, nanoparticle self-assembly process.
Selecta’s targeted Synthetic Vaccine Particle (tSVP™) product platform is based on the combination of scientific breakthroughs in immunobiology and nanotechnology. The tSVP vaccines are rationally designed to deliver bioactive molecules to specific immune cells in the body. Depending on the cellular target and the molecular information encoded in the payload, the tSVP vaccines can potently stimulate or modify immune responses.
Optimal immune response. Immune stimuli are more robust and concentrated when elicited by targeted nanoparticles that contain both antigen and adjuvant than when these are presented as free molecules. Accordingly, Selecta’s tSVP vaccines are specifically designed and configured to generate both strong humoral and cellular immune responses.
Selective targeting. Selecta's tSVP vaccines are designed to freely traffic to the lymph nodes and target cells that mediate antigen presentation. This enables an entirely new class of antigens for disease treatment and prevention, including molecules that are normally not recognized by the immune system. Selective targeting also can enable a new therapeutic approach to treating autoimmune and inflammatory diseases by modulating pathological immune responses.
Controlled adjuvant/ antigen release. Another aspect of the Selecta’s tSVP platform is the ability to optimize and tune the release of antigens and adjuvants to enhance immune responses while sparing adjuvant and antigen dosage and minimizing undesirable systemic side effects. Superior responses can often be generated by tSVP vaccines with a fraction of the antigen and adjuvant required by conventional vaccine technologies.
Proprietary universal T-cell antigen. Selecta has discovered a novel T-cell antigen that is a universal memory epitope which is integrated within tSVP vaccines to boost T-cell help and ensure a rapid and robust immune response.
Biocompatible composition. Selecta's tSVP vaccines are composed of synthetic, biocompatible, biodegradable polymeric materials with established clinical safety profiles from decades of clinical use.
Versatility. Selecta’s tSVP vaccines can present a wide variety of antigens, including proteins, peptides, oligosaccharides and small molecules, to treat or prevent a broad spectrum of diseases including infectious, metabolic, CNS and inflammatory diseases. Additionally, the tSVP platform can incorporate a number of different adjuvants, all with a significant adjuvant sparing effect that can increase efficacy while minimizing or eliminating undesired off-target effects.
Modular nanoparticle engineering. Selecta's proprietary technology platform enables:
(i) the precise and reproducible engineering of tSVP vaccines
(ii) flexibility for use with a wide range of adjuvants and antigen types
(iii) rapid product development enabled by modularity of the tSVP platform
(iv) manufacturing using a readily scalable process with established pharmaceutical unit operations
Selecta's intellectual property portfolio consists of a broad patent estate of issued and pending patent applications covering vaccine nanoparticles, targeted delivery, controlled-release polymer systems, novel adjuvants, novel antigens, and nanoparticle formulation and processing for therapeutic and prophylactic vaccines, and immunomodulatory applications. In addition to its own inventions, Selecta has licensed key foundational intellectual property on an exclusive and worldwide basis from MIT, Brigham and Women's Hospital, and Harvard Medical School.